Beyond the Beat: A Multifaceted Review of Atrial Fibrillation in Sepsis: Risk Factors, Management Strategies, and Economic Impact

Overview

Journal Cardiol Res

Date 2025 Feb 3

PMID 39897439

Authors

Wing Lam Ho

Muhammad Umais

Meena Bai

Ngoc Bao Dang

Kajal Kumari

Sara Izhar

Rabia Asrar

Toleen Haddad

Muhammad Ali Muzammil

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation (AF) is a common arrhythmia in critically ill patients. The objective of this narrative review is to evaluate the characteristics of patients who develop new-onset atrial fibrillation (NOAF) because of sepsis, current management of NOAF in sepsis patients, special consideration in different populations that developed NOAF, health economic and quality of life of patients. We conducted a literature search on PubMed to find research related to NOAF, sepsis and critical illness. Nineteen studies were analyzed for risk factors and outcomes. The incidence rate ranges from 0.53% to 43.9% among these studies. There were numerous risk factors that had been reported from these articles. The most reported risk factors included advanced age, male sex, White race, and cardiovascular comorbidities. The management of septic patients is significantly challenging because of the unfavorable cardiovascular consequences and thromboembolic hazards associated with NOAF. There are comprehensive guidelines available for managing AF, but the effectiveness and safety of therapies in patients with sepsis are still uncertain. Various approaches for managing newly diagnosed AF have been explored. Sinus rhythm can be restored through either pharmacological or non-pharmacological intervention or combination of both. In addition, thromboembolism is a complication that can occur in patients with AF and can have a negative impact on the prognosis of sepsis patients. The use of anticoagulation to prevent stroke after NOAF in sepsis patients is still controversial. Extensive prospective investigations are required to have a deeper understanding of the necessity for anticoagulation following NOAF in sepsis. Beside the treatment of NOAF, early detection of NOAF in sepsis plays a critical role. The prompt initiation of rhythm control medication following a clinical diagnosis of AF can enhance cardiovascular outcomes and reduce mortality in patients with AF and cardiovascular risk factors. Additionally, NOAF in the intensive care unit can prolong hospital stays, increasing hospitalization costs and burdening the hospital. Therefore, preventing and managing NOAF effectively not only benefit the patients but also the hospital in financial aspect. Lastly, to address the existing gaps in knowledge, future research should focus on developing machine learning models that can accurately anticipate risks, establish long-term follow-up protocols, and create complete monitoring systems. The focus is on early intervention and personalized approaches to improve outcomes and quality of life.

References

Bashar S, Ding E, Albuquerque D, Winter M, Binici S, Walkey A . Atrial Fibrillation Detection in ICU Patients: A Pilot Study on MIMIC III Data. Annu Int Conf IEEE Eng Med Biol Soc. 2020; 2019:298-301. DOI: 10.1109/EMBC.2019.8856496. View

Shima N, Miyamoto K, Kato S, Yoshida T, Uchino S . Primary success of electrical cardioversion for new-onset atrial fibrillation and its association with clinical course in non-cardiac critically ill patients: sub-analysis of a multicenter observational study. J Intensive Care. 2021; 9(1):46. PMC: 8268199. DOI: 10.1186/s40560-021-00562-8. View

Savaie M, Sheikhi Y, Baghbanian R, Soltani F, Amiri F, Hesam S . Epidemiology, Risk Factors, and Outcome of Cardiac Dysrhythmias in a Noncardiac Intensive Care Unit. SAGE Open Nurs. 2023; 9:23779608231160932. PMC: 10034271. DOI: 10.1177/23779608231160932. View

Sticherling C, Behrens S, Kamke W, Stahn A, Zabel M . Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Europace. 2005; 7(6):546-53. DOI: 10.1016/j.eupc.2005.05.017. View

Bashar S, Hossain M, Ding E, Walkey A, McManus D, Chon K . Atrial Fibrillation Detection During Sepsis: Study on MIMIC III ICU Data. IEEE J Biomed Health Inform. 2020; 24(11):3124-3135. PMC: 7670858. DOI: 10.1109/JBHI.2020.2995139. View

Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki L, Pettila V . Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005; 31(8):1066-71. DOI: 10.1007/s00134-005-2688-z. View

Brown M, Nassoiy S, Chaney W, Plackett T, Blackwell R, Luchette F . Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit. J Surg Res. 2018; 229:66-75. PMC: 6020161. DOI: 10.1016/j.jss.2018.03.009. View

Steinberg B, Turner J, Lyons A, Biber J, Chelu M, Fang J . Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. Europace. 2019; 22(3):368-374. PMC: 7058971. DOI: 10.1093/europace/euz293. View

Walkey A, McManus D . When Rhythm Changes Cause the Blues: New-Onset Atrial Fibrillation during Sepsis. Am J Respir Crit Care Med. 2017; 195(2):152-154. PMC: 5394791. DOI: 10.1164/rccm.201608-1617ED. View

10.

Walkey A, Quinn E, Winter M, McManus D, Benjamin E . Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis. JAMA Cardiol. 2016; 1(6):682-90. PMC: 5810586. DOI: 10.1001/jamacardio.2016.2181. View

11.

Asanin M, Milika A, Vasiljevic Z, Zorana V, Matic M, Mihailo M . The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation. Clin Cardiol. 2009; 32(8):467-70. PMC: 6653196. DOI: 10.1002/clc.20603. View

12.

Kanji S, Williamson D, Yaghchi B, Albert M, McIntyre L . Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care. 2012; 27(3):326.e1-8. DOI: 10.1016/j.jcrc.2011.10.011. View

13.

Van Gelder I, Groenveld H, Crijns H, Tuininga Y, Tijssen J, Alings A . Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362(15):1363-73. DOI: 10.1056/NEJMoa1001337. View

14.

Merx M, Weber C . Sepsis and the heart. Circulation. 2007; 116(7):793-802. DOI: 10.1161/CIRCULATIONAHA.106.678359. View

15.

Yoshida T, Uchino S, Sasabuchi Y . Clinical course after identification of new-onset atrial fibrillation in critically ill patients: The AFTER-ICU study. J Crit Care. 2020; 59:136-142. DOI: 10.1016/j.jcrc.2020.06.014. View

16.

Lane D, Lip G . Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012; 126(7):860-5. DOI: 10.1161/CIRCULATIONAHA.111.060061. View

17.

Lip G, Tse H, Lane D . Atrial fibrillation. Lancet. 2011; 379(9816):648-61. DOI: 10.1016/S0140-6736(11)61514-6. View

18.

Font M, Thyagarajan B, Khanna A . Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making. Med Clin North Am. 2020; 104(4):573-585. DOI: 10.1016/j.mcna.2020.02.011. View

19.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

20.

Sato R, Kuriyama A, Takada T, Nasu M, Luthe S . Prevalence and risk factors of sepsis-induced cardiomyopathy: A retrospective cohort study. Medicine (Baltimore). 2016; 95(39):e5031. PMC: 5265970. DOI: 10.1097/MD.0000000000005031. View